Skip to main content
. 2022 Jul 26;13:956090. doi: 10.3389/fimmu.2022.956090

Table 1.

LAG3-modulating candidates a .

Drug Phase ClinicalTrials.gov ID Indications Status
Nivolumab/Relatlimab Phase 1 NCT04658147 Hepatocellular Carcinoma Recruiting
Phase 1 NCT02966548 Cancer Active, not recruiting
Phase 1 NCT03335540 Advanced Cancer Active, not recruiting
Phase 1 NCT03044613 Gastric Cancer Active, not recruiting
Phase 1/2 NCT03459222 Advanced Cancer Recruiting
Phase 1/2 NCT02061761 Hematologic Neoplasms Recruiting
Phase 1/2 NCT03310619 Lymphoma Recruiting
Phase 1/2 NCT02488759 Various Advanced Cancer Active, not recruiting
Phase 1/2 NCT03610711 Gastroesophageal Cancer
Immune Checkpoint Inhibition		 Recruiting
Phase 1/2 NCT04611126 Metastatic Ovarian Cancer Recruiting
Phase 1/2 NCT05134948 Advanced Solid Tumors Recruiting
Phase 1/2 NCT03978611 Melanoma Recruiting
Phase 1/2 NCT05337137 Carcinoma, Hepatocellular Recruiting
Phase 1/2 NCT05255601 Lymphoma, Non-Hodgkin
Hodgkin Disease		 Not yet recruiting
Phase 1/2 NCT04150965 Multiple Myeloma Recruiting
Phase 2 NCT04552223 Metastatic Uveal Melanoma Recruiting
Phase 2 NCT04095208 Soft Tissue Sarcoma Adult
Advanced Cancer		 Recruiting
Phase 2 NCT03623854 Chordoma Recruiting
Phase 2 NCT03743766 Melanoma Recruiting
Phase 2 NCT04080804 Head and Neck Squamous
Cell Carcinoma		 Recruiting
Phase 2 NCT04913922 Acute Myeloid Leukemia Recruiting
Phase 2 NCT05002569 Melanoma Recruiting
Phase 2 NCT04112498 Cancer Active, not recruiting
Phase 2 NCT03607890 Refractory MSI-H Solid Tumors Prior of PD-(L) 1 Therapy
MSI-H Tumors		 Recruiting
Phase 2 NCT03642067 Microsatellite Stable (MSS) Colorectal Adenocarcinomas
Colorectal Adenocarcinoma		 Recruiting
Phase 2 NCT03724968 Melanoma Terminated
Phase 2 NCT03704077 Gastric Cancer Withdrawn
Phase 2 NCT02750514 Advanced Cancer Terminated
Phase 2 NCT04567615 Hepatocellular Carcinoma Recruiting
Phase 2 NCT03521830 Basal Cell Carcinoma Recruiting
Phase 2 NCT04326257 Squamous Cell Carcinoma of the Head and Neck Recruiting
Phase 2 NCT04623775 Non-small Cell Lunch Cancer Recruiting
Phase 2 NCT05347212 Carcinomas Not yet recruiting
Phase 2 NCT04205552 NSCLC Stage I/II/IIIA Recruiting
Phase 2 NCT03867799 Metastatic Colorectal Cancer Active, not recruiting
Phase 2 NCT05148546 Renal Cell Carcinoma Recruiting
Phase 2 NCT01968109 Neoplasms by Site Active, not recruiting
Phase 2 NCT03662659 Gastric Cancer Active, not recruiting
Phase 2 NCT02519322 Stage IIIB-IV melanoma Active, not recruiting
Phase 2 NCT04062656 Gastric Cancer Recruiting
Phase 2 NCT02996110 Advanced Cancer Active, not recruiting
Phase 2 NCT02935634 Advanced Gastric Cancer Active, not recruiting
Phase 2 NCT02465060 solid tumors or lymphomas Recruiting
Phase 2/3 NCT03470922 Melanoma Active, not recruiting
Phase 3 NCT05328908 Colorectal Neoplasms Recruiting
Not Applicable NCT04866810 Melanoma Recruiting
Tebotelimab Phase 1 NCT03219268 HER2-positive Advanced Solid Tumors Active, not recruiting
Phase 2 NCT04634825 Head and Neck Cancer, Neoplasms, Squamous Cell Carcinoma Recruiting
Phase 2/3 NCT04082364 Gastric Cancer Active, not recruiting
Chlorogenic acid Phase 1 NCT02728349 Glioblastoma Completed
Phase 1 NCT02245204 Advanced Cancer Completed
Phase 1 NCT02136342 Advanced Cancer Terminated
Phase 1/2 NCT03751592 Advanced Lung Cancer Unknown
RO-7247669 Phase 1 NCT04140500 Solid Tumors Recruiting
Phase 1/2 NCT04524871 Advanced Liver Cancers Recruiting
Phase 1/2 NCT05116202 Melanoma Recruiting
Phase 2 NCT04785820 Advanced or Metastatic Esophageal
Squamous Cell Carcinoma		 Recruiting
Favezelimab Phase 1 NCT02720068 Neoplasms Active, not recruiting
Phase 1/2 NCT04938817 Small Cell Lung Carcinoma Recruiting
Phase 1/2 NCT04626479 Carcinoma, Renal Cell Recruiting
Phase 1/2 NCT05342636 Esophageal Squamous Cell Carcinoma (ESCC) Not yet recruiting
Phase 1/2 NCT03598608 Hodgkin Disease
Lymphoma		 Recruiting
Phase 1/2 NCT04626518 Carcinoma, Renal Cell Recruiting
Phase 2 NCT04895722 Colorectal Cancer Recruiting
Phase 2 NCT03516981 Advanced Non-Small
Cell Lung Cancer		 Active, not recruiting
Phase 3 NCT05064059 Colorectal Cancer Recruiting
INCAGN-2385 Phase 1 NCT03538028 Advanced Malignancies Completed
Phase 1/2 NCT04370704 Melanoma Recruiting
Phase 2 NCT05287113 Head and Neck Cancer Not yet recruiting
Phase 2 NCT04586244 Urothelial Carcinoma Recruiting
IBI-110 Phase 1 NCT04085185 Advanced Malignancies Recruiting
Phase 1 NCT05039658 DLBCL Not yet recruiting
Phase 2 NCT05026593 SCLC Recruiting
Phase 2 NCT05088967 Non-small Cell Lung Cancer Recruiting
Eftilagimod alpha Phase 1 NCT02676869 Stage III/IV Melanoma Completed
Phase 1 NCT04252768 Metastatic Breast Cancer Not yet recruiting
Phase 1 NCT03600090 Solid Tumor, Adult Completed
Phase 2 NCT03625323 Non-small cell lung carcinoma,
head and neck carcinoma		 Active, not recruiting
Phase 2 NCT04811027 HNSCC Recruiting
Phase 2 NCT02614833 Adenocarcinoma
Breast Stage IV		 Completed
Sym-022 Phase I NCT03489369 Metastatic Cancer, Solid Tumor
Lymphoma		 Completed
Phase I NCT04641871 Metastatic Cancer
Solid Tumor		 Recruiting
Phase 1 NCT03311412 Metastatic Cancer, Solid Tumor
Lymphoma		 Completed
Phase I NCT04414150 Malignant Tumors Unknown
Phase 2 NCT05208177 Advanced Solid Tumor Not yet recruiting
LBL-007 Phase 1 NCT04640545 Advanced Melanoma Recruiting
Phase 1/2 NCT05102006 Advanced Solid Tumor Recruiting
ABL-501 Phase I NCT05101109 Advanced Solid Tumor Recruiting
Anti-LAG3 antibody Phase 1 NCT02658981 Glioblastoma Active, not recruiting
HLX 26 Phase I NCT05078593 Solid Tumor Recruiting
IBI-323 Phase I NCT04916119 Advanced Malignancies Recruiting
Ieramilimab Phase 1/2 NCT02460224 Advanced Solid Tumors Completed
FS 118 Phase 1/2 NCT03440437 Advanced Cancer Recruiting
EMB-02 Phase 1/2 NCT04618393 Advanced Solid Tumors Recruiting
Fianlimab Phase 3 NCT05352672 Melanoma Not yet recruiting